Literature DB >> 17239269

NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.

Eleftherios P Mamounas1, Barry Lembersky, Jong-Hyeon Jeong, Walter Cronin, Barbara Harkins, Charles Geyer, Donald Lawrence Wickerham, Soonmyung Paik, Joseph Costantino, Norman Wolmark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17239269     DOI： 10.3816/CBC.2006.n.061

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN： 1526-8209            Impact factor:   3.225


× No keyword cloud information.
  8 in total

Review 1.  Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.

Authors:  Stefan Paepke; Volker R Jacobs; Ralf Ohlinger; Mathias Warm; Sherko Kümmel; Anke Thomas; Nadia Harbeck; Marion Kiechle-Bahat
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-06       Impact factor: 4.553

2.  Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.

Authors:  E M Quinn; C Fleming; M J O'Sullivan
Journal:  Ir J Med Sci       Date:  2015-05-14       Impact factor: 1.568

Review 3.  The Globalization of Cooperative Groups.

Authors:  Manuel Valdivieso; Benjamin W Corn; Janet E Dancey; D Lawrence Wickerham; L Elise Horvath; Edith A Perez; Alison Urton; Walter M Cronin; Erica Field; Evonne Lackey; Charles D Blanke
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

4.  Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.

Authors:  Pattaraporn Wangchinda; Suthinee Ithimakin
Journal:  World J Surg Oncol       Date:  2016-08-24       Impact factor: 2.754

5.  Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.

Authors:  Li Li; Bingmei Chang; Xiaoyue Jiang; Xueke Fan; Yingrui Li; Teng Li; Shanshan Wu; Jun Zhang; Seyed Kariminia; Qin Li
Journal:  BMC Cancer       Date:  2018-10-12       Impact factor: 4.430

6.  Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death.

Authors:  Jianfei Fu; Chenhan Zhong; Lunpo Wu; Dan Li; Tiantian Xu; Ting Jiang; Jiao Yang; Jinlin Du
Journal:  J Breast Cancer       Date:  2019-03-11       Impact factor: 3.588

7.  Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.

Authors:  Camille Moreau-Bachelard; Loïc Campion; Marie Robert; Olivier Kerdraon; Céline Renaudeau; Maud Aumont; Jean-Marc Classe; Mario Campone; Jean-Sébastien Frénel
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

8.  An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.

Authors:  S Verma; S Sehdev; A Joy; Y Madarnas; J Younus; J A Roy
Journal:  Curr Oncol       Date:  2009-07       Impact factor: 3.677
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.